U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cappellini MD, Cohen A, Eleftheriou A, et al. Guidelines for the Clinical Management of Thalassaemia [Internet]. 2nd Revised edition. Nicosia (CY): Thalassaemia International Federation; 2008.

Cover of Guidelines for the Clinical Management of Thalassaemia

Guidelines for the Clinical Management of Thalassaemia [Internet]. 2nd Revised edition.

Show details

REFERENCES

  1. Aessopos A, Stamatelos G, Skoumas V, Vassilopoulos G, Mantzourani M, Loukopoulos D. Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. Chest. 1995;107(1):50–53. [PubMed: 7813310]
  2. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos D. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97:3411–3416. [PubMed: 11369631]
  3. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, Karagiorga M. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127:1523–1530. [PubMed: 15888823]
  4. Aessopos A, Farmakis D. Pulmonary hypertension in beta-thalassemia. Ann N Y Acad Sci. 2005;1054:342–349. [PubMed: 16339682]
  5. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica. 2007;92:658–665. [PubMed: 17488690]
  6. Aessopos A, Farmakis D, Taktikou H, Loukopoulos D. Doppler-determined peak systolic tricuspid pressure gradient in persons with normal pulmonary function and tricuspid regurgitation. J Am Soc Echocardiogr. 2000;13:645–649. [PubMed: 10887347]
  7. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47:792–800. [PubMed: 17465943]
  8. Aessopos A, Karabatsos F, Farmakis D, Katsantoni A, Hatziliami A, Youssef J, Karagiorga M. Pregnancy in patients with well-treated beta-thalassaemia: outcome for mothers and newborn infants. Am J Obstet Gynecol. 1999;180(2 Pt 1):360–365. [PubMed: 9988801]
  9. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol. 1992;82:460–466. [PubMed: 1419829]
  10. Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major [see comments] Blood. 1992;80:593–599. [PubMed: 1638018]
  11. Brecher M, editor. American Association of Blood Banks Technical Manual. 15th Edition. Bethesda, MD: 2005.
  12. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B. Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol. 2006;115(1–2):106–108. [PubMed: 16424659]
  13. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348–355. [PubMed: 15491298]
  14. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;17;360(9332):516–520. [PubMed: 12241655]
  15. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171–2179. [PubMed: 11913479]
  16. Andreani M, Nesci S, Lucarelli G, Tonucci P, Rapa S, et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant. 2000;25:401–404. 2000. [PubMed: 10723583]
  17. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and HCV positivity in determining progression of liver fibrosis in thalassaemia following bone marrow transplantation. Blood. 2002;100:17–21. [PubMed: 12070002]
  18. Angelucci E, Lucarelli G. Bone marrow Transplantation for Thalassemia. In: Steinberg Martin H, Forget Bernard G, Higgs Douglas R, Nagel Ronald L., editors. Disorders of Hemoglobin – Genetics, pathophysiology, and clinical managements. Cambridge University Press; 2001. pp. 1052–1072. Cap 39.
  19. Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassaemia major. N Engl J Med. 2000;3;343(5):327–331. [PubMed: 10922422]
  20. Angelucci E, Giovagnoni A, Valeri G, Paci E, Ripalti M, Muretto P, McLaren C, Brittenham GM, Lucarelli G. Limitations of magnetic resonance imaging in measurement of hepatic iron. Blood. 1997;90:4736–4742. [PubMed: 9389689]
  21. Angelucci E, Muretto P, Lucarelli G, Ripalti M, Baronciani D, Erer B, Galimberti M, Giardini C, Gaziev D, Polchi P. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood. 1997;90:994–998. [PubMed: 9242528]
  22. Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol. 1995;89:757–761. [PubMed: 7772512]
  23. Antoniou M, Grosveld F. Genetic approaches to therapy for the haemoglobinopathies. In: Fairbairn, Testa, editors. Blood Cell Biochemistry, Volume 8: Hematopoiesis and Gene Therapy. New York: Kluwer; 1999. pp. 219–242.
  24. Ansari S, Kivan AA, Tabaroki A. Pregnancy in patients treated for beta thalassaemia major in two centres (Ali Asghar Children's Hospital and Thalassaemia Clinic): outcome for mothers and newborn infants. Pediatr Hematol Oncol. 2006;23:33–37. [PubMed: 16326410]
  25. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long term desferrioxamine treatment. B J Ophthal. 1984;68:873–877. [PMC free article: PMC1040501] [PubMed: 6509007]
  26. Aydinok Y, Evans P, Terzi A, Cetiner N, Porter JB. Randomised Prospective Evaluation of Iron Balance, Chelation Efficiency, Urine Excretion and NTBI Progression with Deferiprone (DFP) or Deferoxamine (DFO) Monotherapy or with Combined DFP Plus DFO. Blood (ASH Annual Meeting Abstracts). 2005;106 Abstract 2698.
  27. Bank A, Dorazio R, Leboulch P. A phase I/II clinical trial of b-globin gene therapy for bthalassaemia. Ann N Y Acad Sci. 2005;1054:308–316. [PubMed: 16339679]
  28. Berdoukas VA, Kwan YL, Sansotta ML. A study on the value of red cell exchange transfusion in transfusion dependent anaemias. Clin Lab Haematol. 1986;8(3):209–220. [PubMed: 3093137]
  29. Blake DR, Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JMC, Rowley D, Halliwell B, Cornish A, Hider RC. Cerebral and ocular toxicity induced by desferrioxamine. Quarterly Journal of Medicine. 1985;56:345–355. [PubMed: 4095247]
  30. Boone KE, Watters DA. The incidence of malaria after splenectomy in Papua New Guinea. Br Med J. 1995;311(7015):1273. [PMC free article: PMC2551185] [PubMed: 7496237]
  31. Boosalis MS, Bandyopadhyay R, Bresnick EH, et al. Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood. 2001;97:3259–3267. [PMC free article: PMC4263369] [PubMed: 11342457]
  32. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in Desferrioxamine or Deferiprone-treated patients with thalassaemia major. Blood. 2006;107(9):3733–3737. [PubMed: 16373663]
  33. Borgna-Pignatti C. Thalassaemia. A few new tiles in a large mosaic. Haematologica. 2006;91(9):1159–1161. Review. [PubMed: 16956812]
  34. Borgna-Pignatti C, Rigon F, Merlo L, et al. Thalassaemia minor, the Gilbert mutation, and the risk of gallstones. Haematologica. 2003;88:1106–1109. [PubMed: 14555305]
  35. Borgna-Pignatti C, Rugolotto S, De SP, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187–1193. [PubMed: 15477202]
  36. Bosquet J, Navarro M, Robert G, Aye P, Michel FB. Rapid desensitisation for desferrioxamine anaphylactoid reaction. Lancet. 1983;2:859–860. [PubMed: 6137689]
  37. Bourantas K, Economou G, Georgiou J. Administration of high doses of recombinant human erythropoietin to patients with beta-thalassaemia intermedia: a preliminary trial. Eur J Haematol. 1997;58:22–25. [PubMed: 9020369]
  38. Brecker M, editor. Technical Manul. 14TH ed. Bethesda, MD: American Association of Blood Banks; 2003. p. 162.
  39. Brecker M. Technical Manul. 14TH ed. Bethesda, MD: American Association of Blood Banks; 2003. p. 183.
  40. Brittenham GM, Griffith PM, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major. New Eng J Med. 1994;331(9):567–573. [PubMed: 8047080]
  41. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42(1):81–85. [PubMed: 8416302]
  42. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassaemia major. N Engl J Med. 1990;323(11):713–719. [PubMed: 2388669]
  43. Buchholz DH, AuBuchon JP, Snyder EL, Kandler R, Edberg S, Piscitelli V, Pickard C, Napychank P. Removal of Yersinia enterocolitica from AS-1 red cells. Transfusion. 1992;32:667–672. [PubMed: 1519330]
  44. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971;51(2):209–221. [PubMed: 5095527]
  45. Butwick A, Findley I, Wonke B. Management of pregnancy in a patient with beta thalassaemia major. Int J Obstet Anesth. 2005;14:351–354. [PubMed: 16140004]
  46. Camaschella C, Cappellini MD. Thalassaemia intermedia. Haematologica. 1995;80:58–68. [PubMed: 7758995]
  47. Cao A, Jung M, Stamatoyannopoulos G. Hydroxamic acid derivatives induce g globin gene expression in vivo [abstract] Blood Cells Mol Dis. 2005;34:80.
  48. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455–3462. [PubMed: 16352812]
  49. Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol. 2005;42:S19–S21. [PubMed: 15846581]
  50. Cappellini MD, Cerino M, Marelli S, Fiorelli G. Thalassaemia intermedia: clinical aspects and management. Haematologica. 2001;86 Suppl 1:194–196.
  51. Cappellini MD, Graziadei G, Ciceri L, et al. Oral isobutyramide therapy in patients with thalassemia intermedia: Results of a phase II open study. Blood Cells Mol Dis. 2000;26:105–111. [PubMed: 10772882]
  52. Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomised patients with thalassaemia intermedia. Br J Haematol. 2000;111:467–473. [PubMed: 11122086]
  53. Carmina E, Di Fede G, Napoli N, et al. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassaemia major. Calcif Tissue Int. 2004;74:68–71. [PubMed: 14523599]
  54. Castelli R, Graziadei G, Karimi M, Cappellini MD. Intrathoracic masses due to extramedullary haematopoiesis. Am J Med Sci. 2004;328:299–303. [PubMed: 15545849]
  55. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277–287. [PubMed: 15737890]
  56. Cazzola M, Borgna-Pignatti C, et al. A moderate transfusion regimen may reduce iron loading in beta-thalassaemia major without producing excessive expansion of erythropoiesis. Transfusion. 1997;37(2):135–140. [PubMed: 9051086]
  57. Cazzola M, DeStefano P, Ponchio L, Locatelli F, Beguin Y, Dessi C, Barella S, Cao A, Galanello R. Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major. Br J Haem. 1995;89:473–478. [PubMed: 7734344]
  58. Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, et al. Risk factors for death in patients with b-thalassaemia major: results of a case-control study. Haematologica. 2006;91(10):1420–1421. [PubMed: 16963395]
  59. Ceci A, Baiardi P, Felisi M, Cappellini MD, Carnelli V, De Sanctis V, Galanello R, Maggio A, Masera G, Piga A, Schettini F, Stefano I, Tricta F. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330–336. [PubMed: 12100170]
  60. Centis F, Tabellini L, Lucarelli G, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood. 2000;96:3624–3629. [PubMed: 11071663]
  61. Chan YL, Pang LM, Chik KW, Cheng JC, Li CK. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol. 2002;32:492–497. [PubMed: 12107582]
  62. Chatterjee R, G M, Helal MA. Hypogonadism is a key contributor to the severity of osteoporosis in thalassaemic patients. 10th International Federation Conference (TIF); October 18–21, 2001.
  63. Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf). 2000 Jul;53(1):33–42. [PubMed: 10931078]
  64. Chehal A, Aoun E, Koussa S, et al. Hypertransfusion: a successful method of treatment in thalassaemia intermedia patients with spinal cord compression secondary to extramedullary haematopoiesis. Spine. 2003;28:E245–E249. [PubMed: 12838112]
  65. Chiodo AA, Alberti PW, Sher GD, Francombe WH, Tyler B. Desferrioxamine ototoxicity in an adult transfusion-dependent population. J Otolaryngol. 1997;26:116–122. [PubMed: 9106087]
  66. Choudhry VP, Pati HP, Saxena A, Malaviya AN. Deferiprone, efficacy and safety. Indian J Pediatr. 2004;71:213–216. [PubMed: 15080407]
  67. Chung BH, Ha SY, Chan GC, Chiang A, Lee TL, Ho HK, Lee CY, Luk CW, Lau YL. Klebsiella infection in patients with thalassaemia. Clin. Infect. Dis. 2003;36(5):575–579. [PubMed: 12594637]
  68. Cohen A, Masera G, Zoumbos N, Uysal Z, Boulet D, Watman N, Loggetto S, Opitz H, Gathmann I, Alberti D. Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasisox. Blood. 2005;106 Abstract 622.
  69. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood. 2003;102:1583–1587. [PubMed: 12763939]
  70. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108:305–312. [PubMed: 10691860]
  71. Cohen A, Markenson AL, Schwarz E. Transfusion requirements and splenectomy in thalassaemia major. Journal of Paediatrics. 1980;97:100–102. [PubMed: 7381628]
  72. Cohen AR, Mizanin J, Schwarz E. Rapid removal of excessive iron with daily, high dose, intravenous chelation therapy. J Pediatr. 1989;115(1):151–155. [PubMed: 2738783]
  73. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassaemia: a clinical trial. Blood. 1995;85:39–43. [PubMed: 7528572]
  74. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991;325:675–680. [PubMed: 1651452]
  75. Constantoulakis P, Knitter G, Stamatoyannopoulos G. On the induction of foetal haemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood. 1989;74:1963–1971. [PubMed: 2478217]
  76. Daar S, Taher A, Pathare A, Krahn U, Gathmann I, Nick H, Hadler D. Plasma LPI in Thalassemia Patients before and after Treatment with Deferasirox (Exjade®, ICL670). Blood. 2005;106 Abstract 2697.
  77. Daskalakis GJ, Papageorgiou IS, Antsaklis AJ, Michalas SK. Pregnancy and homozygous beta thalassaemia major. Br J Obstet Gynaecol. 1998;105:1028–1032. [PubMed: 9763058]
  78. Davies SC, Marcus RE, Hungerford JL, Miller HM, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2:181–184. [PubMed: 6135026]
  79. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood. 2004;104:263–269. [PubMed: 15001468]
  80. Davis BA, Porter JB. Results of long term iron chelation treatment with deferoxamine. Adv Exp Med Biol. 2002;509:91–125. [PubMed: 12572991]
  81. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 2000;95:1229–1236. [PubMed: 10666195]
  82. Deech R. Legal and ethical responsibilities of gamete banks. Hum Reprod. 1998 May;13 Suppl 2:80–83. discussion 84– 9. Review. [PubMed: 9665328]
  83. Deugnier Y. Human hepatic iron overload syndromes. Bull Acad Natl Med. 2005;189(8):1665–1667. [PubMed: 16737093]
  84. De Virgillis S, Congia M, Frau F, Argiolu F, Diana G, Cucca F, Varsi A, Sanna G, Podda G, Fodde M. Desferrioxamine-induced growth retardation in patients with thalassaemia major. Journal of Pediatrics. 1988;113:661–669. [PubMed: 3171791]
  85. Del Vecchio GC, Schettini F, Piacente L, De Santis A, Giordano P, De Mattia D. Effects of deferiprone on immune status and cytokine pattern in thalassaemia major. Acta Haematol. 2002;108(3):144–149. [PubMed: 12373086]
  86. Dettelbach HR, Aviado DM. Clinical pharmacology of pentoxifylline with special reference to its haemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol. 1985;25:8–26. [PubMed: 3882773]
  87. Dini G, Miano M, Morreale G, Lanino E. Transplantation of bone marrow from unrelated donors in Italy:activity and results. Ann 1st Super Sanita. 1999;35(1):7–11. [PubMed: 10645639]
  88. Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassaemia intermedia-a promising therapy. Ann Hematol. 2005;84:441–446. [PubMed: 15838670]
  89. Dunbar C, Travis W, Kan YW, Nienhuis AW. 5-Azacytidine treatment in a beta (0)-thalassemic patient unable to be transfused due to multiple allo-antibodies. Br J Haematol. 1989;72:467–468. [PubMed: 2475157]
  90. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassaemia. Blood. 2002;99:36–43. [PubMed: 11756150]
  91. Evered DC, Ormston BJ, Smith PA, Hall R, Bird T. Grades of hypothyrodism. BMJ. 1973;I:657–662. [PMC free article: PMC1588654] [PubMed: 4120849]
  92. Fathallah H, Atweh GF. Induction of foetal haemoglobin in the treatment of sickle cell disease. Hematology, Am Soc Hematol Educ Program. 2006:58–62. [PubMed: 17124041]
  93. Fiorelli G, Fargion S, Piperno A, et al. Iron metabolism in thalassaemia intermedia. Haematologica. 1990;75 Suppl 5:89–95. [PubMed: 2086386]
  94. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol. 2003;121:938–948. [PubMed: 12786807]
  95. Freeman AP, Giles RW, Berdoukas VA, Walsh WF, Choy D, Murray PC. Early left ventricular dysfunction and chelation therapy in thalassemia major. Ann Intern Med. 1983;99:450–454. [PubMed: 6625375]
  96. Friedman DF, Jawad AF, Martin MB, Horiuchi K, Mitchell CF, Cohen AR. Erythrocytapheresis to reduce iron loading in thalassemia. Blood. 2003;102:121a.
  97. Fucharoen S, Siritanaratkul N, Winichagoon P, et al. Hydroxyurea increases HbF levels and improves the effectiveness of erythropoiesis in beta thalassaemia/HbE disease. Blood. 1996;87:887–892. [PubMed: 8562958]
  98. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26–36. [PubMed: 8604584]
  99. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, Ladis V, Voi V, Lund U, Tricta F. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006a;91:1241–1243. [PubMed: 16956824]
  100. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006b;91:1343–1351. [PubMed: 17018383]
  101. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003;43:565–572. [PubMed: 12817519]
  102. Galanello R, Piras S, Barella S, et al. Cholelithiasis and Gilbert's syndrome in homozygous beta-thalassaemia. Br J Haematol. 2001;115:926–928. [PubMed: 11843828]
  103. Gambari R, Fibach E. Medicinal chemistry of foetal haemoglobin inducers for treatment of b-thalassaemia. Curr Med Chem. 2007;14:199–212. [PubMed: 17266579]
  104. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815–820. [PubMed: 8596547]
  105. Gimmon Z, Wexler WR, Rachmilewitz EA. Juvenile leg ulceration in beta-thalassaemia major and intermedia. Plast Reconstr Surg. 1982;69:320–325. [PubMed: 7034014]
  106. Global Report on Birth Defects, March of Dimes, 24–25 (2006).
  107. Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr. 2004;41:21–27. [PubMed: 14767084]
  108. Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin. 2006;30:263–274. [PubMed: 16798652]
  109. Han XD, Lin C, Chang J, Sadelain M, Kan YW. Fetal gene therapy of alfa-thalassaemia in a mouse model. Proc Natl Acad Sci USA. 104:9007–9011. [PMC free article: PMC1885618] [PubMed: 17496141]
  110. Haemoglobin E-beta-thalassemia. Thalassemia International Federation; 2002. chapter 12.
  111. Hershko C, Rachmilewitz E. Mechanism of desferrioxamine induced iron excretion in thalassaemia. Brit. J. Haematol. 1979;42:125–132. [PubMed: 465354]
  112. Hoffbrand AV, F AL-R, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B. Long-term trial of deferiprone in 51 transfusiondependent iron overloaded patients. Blood. 1998;91:295–300. [PubMed: 9414297]
  113. Hui L, Leung MP, Ha SY, Chau AK, Cheung YF. Early detection of left ventricular dysfunction in patients with beta-thalassaemia major by dobutamine stress echocardiography. Heart. 2003;89:669–670. [PMC free article: PMC1767681] [PubMed: 12748234]
  114. Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, Sharara AI. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol. 2005;130:644–646. [PubMed: 16098081]
  115. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood. 2003;101:91–96. [PubMed: 12393528]
  116. von Kalle C, Baum C, Williams DA. Lenti in red: progress in gene therapy for human haemoglobinopathies. J Clin Invest. 2004;114:889–891. [PMC free article: PMC518672] [PubMed: 15467825]
  117. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassaemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr. Hematol. Oncol. 2005;27:380–385. [PubMed: 16012328]
  118. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papasotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis. 2006;36:21–25. [PubMed: 16386928]
  119. Krajaejun T, Sathapatayavongs B, Pracharktam R, Nitiyanant P, Leelachaikul P, Wanachiwanawin W, et al. Clinical and epidemiological analyses of human pythiosis in Thailand. Clin Infect Dis. 2006;43(5):569–576. [PubMed: 16886148]
  120. Landgren O, Bjorkholm M, Konradsen HB, Soderqvist M, Nilsson B, Gustavsson A, et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomised individuals with special reference to Hodgkin's lymphoma. J Intern Med. 2004;255(6):664–673. [PubMed: 15147530]
  121. Lasco A, Morabito N, Gaudio A, et al. Osteoporosis and beta-thalassaemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest. 2002;25:338–344. [PubMed: 12030605]
  122. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassaemia major. Osteoporos Int. 2001;12:570–575. [PubMed: 11527055]
  123. Lavelle D, Vaitkus K, Hankewych M, Singh M, DeSimone J. Effect of 5-aza-2’-deoxycytidine (Dacogen) on covalent histone modifications of chromatin associated with the epsilon-, gamma-, and beta-globin promotrs in Papio anubis. Exp Hematol. 2006;34(3):339–347. [PubMed: 16543068]
  124. Leandros E, et al. Hand-assisted laparoscopic surgery with a Pfannenstiel incision in beta-thalassaemia patients: initial experience. World J Surg. 2006;30:1216–1220. [PubMed: 16773256]
  125. Lefrere JJ, Maniez-Montreuil M, Morel P, Defer C, Laperche S. Safety of blood products and B19 parvovirus. Transfus Clin Biol. 2006;13(4):235–241. [PubMed: 16822687]
  126. Leung CF, Lao TT, Chang AM. Effect of folate supplement on pregnant women with beta-thalassaemia minor. Eur J Obstet Gynecol Reprod Biol. 1989;33:209–213. [PubMed: 2599250]
  127. Levings PP, Bungert J. The human b-globin locus control region. Eur J Biochem. 2002;269:1589–1599. [PubMed: 11895428]
  128. Ley TJ, DeSimone J, Anagou NP, et al. 5-Azacytidine selectively increases g-globin synthesis in a patient with beta+ - thalassaemia. N Eng J Med. 1982;307:1469–1475. [PubMed: 6183586]
  129. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. Br J Haematol. 2002;117:755–758. [PubMed: 12028054]
  130. Lowrey CH, Nienhuis AW. Brief report: treatment with azacitidine of patients with end-state b-thalassaemia. N Eng J Med. 1993;329:945. [PubMed: 7689171]
  131. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C, Politi P, Durazzi SM, Muretto P, Albertini F. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417–421. [PubMed: 2300104]
  132. Edt Lucarelli G, et al. Proceedings of the Third International Symposium on Bone Marrow Transplantation in Thalassaemia, Pesaro, 1996. Bone Marrow Transplantation. 1997;19 Suppl.2
  133. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, Di Gregorio F, Garozzo G, Malizia R, Magnano C, Mangiagli A, Quarta G, Rizzo M, D'Ascola DG, Rizzo A, Midiri M. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis. 2002;28:196–208. [PubMed: 12064916]
  134. Mahachoklertwattana P. Zoledronic acid for the treatment of thalassaemia-induced osteonecrosis. Haematologica. 2006 Sep;91(9):1155A. [PubMed: 16956807]
  135. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease. Clin Endocrinol (Oxf). 2003;58:273–279. [PubMed: 12608931]
  136. Mankidy R, Faller DV, Mabaera R, Lowrey C, Boosalis M, White G, Castaneda SC, Perrine SP. Dissociation of an HDA-3/ NCoR repressor complex is associated with high-level induction of the gamma-globin gene promoter by potent SCFAD. Blood. 2006;108:3179–3186. [PMC free article: PMC1895523] [PubMed: 16849648]
  137. March of Dimes. Global Report on Birth Defects. 2006.
  138. Marcus RE, Davies SC, Bantock HM, Underwood SR, Walton S, Huehns ER. Desferrioxamine to improve cardiac function in iron-overloaded patients with thalassemia major. Lancet. 1984;1(8373):392–393. [PubMed: 6141447]
  139. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digest Liver Dis. 2007 doi: 10.1016/j.dld.2006.12.017. [PubMed: 17382608]
  140. May C, Rivella S, Callegari J, Heller G, Gaenslerk KML, Luzzatto L, Sadelain M. Therapeutic haemoglobin synthesis in b-thalassaemic mice expressing lentivirus-encoded human b-globin. Nature. 2000;406:82–86. [PubMed: 10894546]
  141. Miano M, Labopin M, Hartmann O, Angelucci E, Cornish J, Gluckman E, Locatelli F, Fischer A, Egeler RM, Or R, Peters C, Ortega J, Veys P, Bordigoni P, Iori AP, Niethammer D, Rocha V, Dini G. Trends of Haematopoietic Stem cell Transplantation in Children during the last 3 decades: a survey from the Paediatric Diseases Working Party of the European Blood and Bone Marrow Transplantation Group. Bone Marrow Transplant. 2007;39:89–99. [PubMed: 17213848]
  142. Michail-Merianou V, Pamphili-Panousopoulou L, Piperi-Lowes L, Pelegrinis E, Karaklis A. Alloimmunization to red cell antigens in thalassemia: comparative study of usual versus better-match transfusion programmes. Vox Sanguinis. 1987;52:95–98. [PubMed: 3300026]
  143. Miccio A, Cesari R, Lotti F, Rossi C, Tiboni F, Sanvito F, Ponzoni M, Routledge S, Antoniou M, Ferrari G. Long-term correction of b-thalassaemia by transplantation of transduced hematopoietic stem cells. Mol Ther. 2006;13 Supplement 1:S30.
  144. Miller KB, Rosenwasser LJ, et al. Rapid desensitisation for desferrioxamine anaphylactic reaction. Lancet. 1981;(i):1059. [PubMed: 6112440]
  145. Miniero R, Rocha V, Saracco P, Locatelli F, Brichard B, Nagler A, Roberts I, Yaniv I, Beksac M, Bernaudin F, Gluckman E. Cord blood transplantation (CBT) in hemoglobinopathies. Eurocord. Bone Marrow Transplant. 1998;22 Suppl 1:S78–S79. [PubMed: 9715898]
  146. de Montalembert M, Girot R, Revillion Y, Jan D, Adjrad L, Ardjoun FZ, Belhani M, Najean Y. Partial splenectomy in homozygous β-thalassaemia. Arch Dis Child. 1990;65:304–307. [PMC free article: PMC1792263] [PubMed: 2334210]
  147. Modell B. Total management of thalassaemia major. Arch Dis Child. 1977;52(6):489–500. [PMC free article: PMC1544709] [PubMed: 879834]
  148. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N. Osteoprotegerin and RANKL in the pathogenesis of thalassaemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res. 2004;19:722–727. [PubMed: 15068494]
  149. Morell A. Pathogen inactivation of labile blood products. Bern Switzerland: ZLB Central Laboratory Swiss Red Cross; 2000.
  150. Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121:187–189. [PubMed: 12670352]
  151. Muretto P, Angelucci E, Lucarelli G. Reversibility of Cirrhosis in Patients Cured of Thalassemia by Bone Marrow Transplantation. Ann Intern Med. 2002;136:667–672. [PubMed: 11992302]
  152. Nassar AH, Usta IM, Rechdan JB, Koussa S, Inati A, Taher AT. Pregnancy in patients with beta-thalassaemia intermedia: outcome of mothers and newborns. Am J Hematol. 2006;81:499–502. [PubMed: 16755576]
  153. National Evidence-Based Clinical Guidelines Fertility: assessment and treatment for people with fertility problems_. Feb, 2004. http://www​.rcog.org.uk. [PubMed: 21089236]
  154. Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006;13:1031–1049. [PubMed: 16624621]
  155. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597–1602. [PubMed: 12747879]
  156. Nisli G, Kavakli K, Vergin C, Oztop S, Cetingul N. Recombinant human erythropoietin trial in thalassaemia intermedia. J Trop Pediatr. 1996;42:330–334. [PubMed: 9009557]
  157. Olivieri NF. The beta-thalassaemias. N Engl J Med. 1999;341:99–109. [PubMed: 10395635]
  158. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major [see comments] N Engl J Med. 1998;339:417–423. [PubMed: 9700174]
  159. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997a;89:739–761. [PubMed: 9028304]
  160. Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet. 1997;350:491–492. [PubMed: 9274590]
  161. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med. 1995;332:918–922. [PubMed: 7877649]
  162. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. New England Journal of Medicine. 1994;331:574–578. [PubMed: 8047081]
  163. Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, Bailey JD, Reilly BJ. Growth failure and bony changes induced by deferoxamine. American Journal of Pediatric Hematology Oncology. 1992;14:48–56. [PubMed: 1550263]
  164. Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, McClelland RA, Templeton DM. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet. 1990;336:1275–1279. [PubMed: 1978115]
  165. Olivieri NF, Buncie JR, Chew E, Gallanti T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freeman MH. Visual and auditory neurotoxicity in patients receiving subcutaneous desferrioxamine infusions. New England Journal of Medicine. 1986;314(14):869–873. [PubMed: 3485251]
  166. Origa R, Bina P, Agus A, Crobu G, Defraia E, Dessi C, Leoni G, Muroni PP, Galanello R. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica. 2005;90:1309–1314. [PubMed: 16219566]
  167. Origa R, Fiumana E, et al. Osteoporosis in beta-thalassaemia: Clinical and genetic aspects. Ann N Y Acad Sci. 2005;1054:451–456. [PubMed: 16339696]
  168. Orr D. Difficult intubation: a hazard in thalassaemia. A case report. Br J Anaesth. 1967;39:585–586. [PubMed: 6037376]
  169. Pace BS, Zein S. Understanding mechanisms of γ-globin gene regulation to develop strategies for pharmacological foetal haemoglobin induction. Developmental Dynamics. 2006;235:1727–1737. [PubMed: 16607652]
  170. Pedersen FK. Post-splenectomy infections in Danish children splenectomised 1969–1978. Acta Ped Scand. 1983;72:589–595. [PubMed: 6624435]
  171. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738–3744. [PubMed: 16352815]
  172. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, et al. Evaluation of the efficacy of oral Deferiprone in beta-thalassaemia major by multislice multiecho T2*. Eur. J. Haematol. 2006;76(3):183–192. [PubMed: 16451393]
  173. Perera D, Pizzey A, Campbell A, Katz M, Porter J, Petrou M, Irvine DS, Chatterjee R. Sperm DNA damage in potentially fertile homozygous beta-thalassaemia patients with iron overload. Hum Reprod. 2002;17:1820–1825. [PubMed: 12093845]
  174. Perrine SP, Castaneda SA, Boosalis MS, White GL, Jones BM, Bohacek R. Induction of foetal globin in beta-thalassaemia: Cellular obstacles and molecular progress. Ann N Y Acad Sci. 2005;1054:257–265. [PMC free article: PMC4261694] [PubMed: 16339673]
  175. Perrine SP. Haemoglobin F-new targets, new path. Blood. 2006;108:783–784.
  176. Perrine SP. Foetal globin induction - Can it cure beta-thalassaemia? Hematology, Am Soc Hem Education Programme. 2005 December [PMC free article: PMC4262245] [PubMed: 16304357]
  177. Perrine SP, Ginder G, Faller DV, et al. A short-term trial of butyrate to stimulate foetal-globin-gene expression in the beta-globin disorders. N Eng J Med. 1993;328:129–131. [PubMed: 7677966]
  178. Persons DA, Tisdale JF. Gene therapy for the haemoglobin disorders. Semin Hematol. 2004;41:279–286. [PubMed: 15508113]
  179. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–880. [PubMed: 16818273]
  180. Piga A, Galggioti C, Rogliacco E, Tricta F. Comparative effects of Deferiprone and Desferrioxamine on survival and cardiac disease in patients with thalassaemia major: a retrospective analysis. Haemtologica. 2003;88(5):489–496. [PubMed: 12745268]
  181. Piga A, Luzzatto L, Capalbo P, Gambotto S, Tricta F, Gabutti V. High dose desferrioxamine as a cause of growth failure in thalassaemic patients. European Journal Haematology. 1988;40:380–381. [PubMed: 3366230]
  182. Pippard M, Johnson D, Callender S, Finch C. Ferrioxamine excretion in iron loaded man. Blood. 1982;60:288–294. [PubMed: 7093519]
  183. Pippard MJ, Callender ST, Warner GT, Weatherall DJ. Iron absorption and loading in beta-thalassaemia intermedia. Lancet. 1979;2:819–821. [PubMed: 90918]
  184. Pootrakul P, Vongsmasa V, Laongpanich P, Wasi P. Serum ferritin levels in thalassaemia and the effect of splenectomy. Acta Haematologica. 1981;12:90–93. [PubMed: 6800190]
  185. Porter JB. Monitoring and treatment of iron overload: state of the art and new approaches. Semin Hematol. 2005;42:S14–S18. [PubMed: 15846580]
  186. Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved Myocardial T2* in Transfusion Dependent Anemias Receiving ICL670 (Deferasirox). Blood. 2005;106:1003a. Abstract 3600.
  187. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with desferrioxamine therapy. Blood. 1996;88:705–714. [PubMed: 8695819]
  188. Porter JB, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 2002;15:329–368. [PubMed: 12401311]
  189. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73:403–409. [PubMed: 2605127]
  190. Premawardhena, et al. HaemoglobinE-β-Thalassaemia: Progress Report from the International Study Group. Ann NY Acad Sci. 2005;1054:33–39. [PubMed: 16339649]
  191. Pringle KC, Spigos DG, Tan WS, Politis C, Pang EJ, Reyez HM, et al. Partial splenic embolisation in the management of thalassaemia major. J Pediatr Surg. 1982;017(6):884–891. [PubMed: 7161675]
  192. Rachmilewitz EA, Aker M. The role of recombinant human erythropoietin in the treatment of thalassaemia. Ann N Y Acad Sci. 1998;850:129–138. [PubMed: 9668535]
  193. Rahav G, Volach V, Shapiro M, Rund D, Rachmilewitz EA, Goldfarb A. Severe infections in thalassaemic patients: prevalence and predisposing factors. Br J Haematol. 2006;133(6):667–674. [PubMed: 16704445]
  194. RCOG clinical Green Top Guidelines. Management of HIV in Pregnancy (39) - April 2004. http://www​.rcog.org.uk.
  195. Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Lancet. 1991;337:277–280. [PubMed: 1671122]
  196. Reich S, Buhrer C, Henze G, et al. Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassaemia. Blood. 2000;96:3357–3363. [PubMed: 11071627]
  197. Report of a joint WHO/March of Dimes Meeting; 5 – 15, May 2006.
  198. Rivella S, May C, Chadburn A, Rivière I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human b-globin gene transfer. Blood. 2003;101:2932–2939. (2003) [PubMed: 12480689]
  199. Roselli EA, Cesari R, Miccio A, Tiboni F, Corbella P, Rossi C, Biral E, Marktel S, Antoniou M, Andreani M, Lucarelli G, Ferrari G. Gene Therapy for b-thalassaemia: Preclinical studies on human cells. Mol Ther. 2006;13 Supplement 1:S257.
  200. Sabato AR, de Sanctis V, Atti G, Capra L, Bagni B, Vullo C. Primary hypothyroidism and the low T3 syndrome in thalassaemia major. Arch Dis Child. 1983;58(2):120–127. [PMC free article: PMC1628103] [PubMed: 6830288]
  201. de Sanctis V, Eleftheriou A, Malaventura C. on behalf of the Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of Endocrine Complications and Short Stature in Patients with Thalassaemia major: A Multicenter Study by the Thalassaemia International Federation (TIF). Ped Endocrinol Rev. 2004;2 Suppl 2:249–255. [PubMed: 16462705]
  202. de Sanctis V, Urso L. Clinical experience with growth hormone treatment in patients with beta-thalassaemia major. BioDrugs. 1999;11:79–85. [PubMed: 18031117]
  203. de Sanctis V, Pintor C, et al. Multicentre study on endocrine complications in thalassaemia major. Clinical Endocrinology. 1995;42:581–586. [PubMed: 7634497]
  204. de Sanctis V, Atti G, Banin P, Orzincolo C, Cavallini AR, Patti D, Vullo C. Growth in thalassaemia major. Acta Med Auxol. 1991;23:29–36.
  205. Sadelain M. Recent advances in globin gene transfer for the treatment of b-thalassaemia and sickle cell anaemia. Curr Opin Hematol. 2006;13:142–148. [PubMed: 16567956]
  206. Sambrook P, Cooper C. Osteoporosis. Lancet. 2006 2010 Jun 17;367(9527) Review. [PubMed: 16782492]
  207. Saxon BR, Rees D, Olivieri NF. Regression of extramedullary haemopoiesis and augmentation of foetal haemoglobin concentration during hydroxyurea therapy in beta-thalassaemia. Br J Haematol. 1998;101:416–419. [PubMed: 9633880]
  208. Sharara AI, Aoun E, Koussa S, Inati A, Taher A. Treatment of acute hepatitis C in a child with thalassemia major using weight-based peginterferon alpha-2b. J Gastroenterol Hepatol. 2006;21:1221. [PubMed: 16824084]
  209. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med. 1996;125:658–668. [PubMed: 8849151]
  210. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996;88:1576–1582. [PubMed: 8781412]
  211. Singer DB. Postsplenectomy sepsis. Perspect Pediatr Pathol. 1973;1:285–311. 285–311. [PubMed: 4596312]
  212. Singer ST, Sweeters N, Vichinsky E, Wagner AJ, Rachmilewitz EA. A dose-finding and safety study of darbepoetin alfa (erythropoiesis stimulating protein) for the treatment of anaemia in patients with thalassaemia intermedia [abstract] Blood. 2003;102:268a.
  213. Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood. 2000;96:3369–3373. [PubMed: 11071629]
  214. Singer ST, Vichinsky EP. Deferoxamine treatment during pregnancy: is it harmful? Am J Hematol. 1999;60:24–26. [PubMed: 9883802]
  215. Skordis N, Christou S, Koliou M, Pavlides N, Angastiniotis M. Fertility in female patients with thalassaemia. J Pediatr Endocrinol Metab. 1998;11 Suppl 3:935–943. [PubMed: 10091168]
  216. Spanos T, Ladis V, Palamidou F, Papassotiriou I, Banagi A, Premetis E, Kattamis C. The impact of neocyte transfusion in the management of thalassaemia. Vox Sanguinis. 1996;70:217–23. [PubMed: 9123927]
  217. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox Sanguini. 1990;58:50–55. [PubMed: 2316211]
  218. Spoulou VI, Tsoumas DL, Ladis V, Spentzou A, Theodoridou MC. Natural and vaccine-induced immunity against Haemophilus influenzae type b in patients with beta-thalassaemia. Vaccine. 2006;24(16):3050–3053. [PubMed: 16519975]
  219. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105:855–861. [PubMed: 15256427]
  220. Stamatoyannopoulos G. Prospects for developing a molecular cure for thalassemia. Hematology. 2005;10 Suppl 1:255–257. [PubMed: 16188685]
  221. Swanson K, Dwyre DM, Krochmal J, Raife TJ. Transfusion-related acute lung injury (TRALI): current clinical and pathophysiologic considerations. Lung. 2006;184:177–185. [PubMed: 16902843]
  222. Taher A, Abou-Mourad Y, Abchee A, et al. Pulmonary thromboembolism in beta-thalassaemia intermedia: are we aware of this complication? Hemoglobin. 2002;26:107–112. [PubMed: 12144052]
  223. Taher A, Ismaeel H, Cappellini MD. Thalassaemia Intermedia: Revisited. Blood Cells Mol Dis. 2006;37:12–20. [PubMed: 16737833]
  224. Taher A, Ismaeel H, Mehio G, Bignamini D, et al. The incidence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96:488–491. [PubMed: 17003927]
  225. Tanner MA, Galanello R, Dessi C, et al. A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance. Circulation. 2007 April 10;115(14):1876–1884. [PubMed: 17372174]
  226. Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassaemia major on deferoxamine chelation. J Cardiovasc Magn Reson. 2006;8(3):543–547. [PubMed: 16755844]
  227. Tanner JM. Growth at adolescence. 2nd Ed. Springfield: Charles C Thomas Publisher; 1962.
  228. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110:971–977. [PubMed: 11054091]
  229. Thalassemia International Federation. Haemoglobin E-beta-thalassaemia. 2002. Chap. 12.
  230. Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. British Journal of Haematology. 1998;101:413–415. [PubMed: 9633879]
  231. Tuck SM, Jensen CE, Wonke B, Yardumian A. Pregnancy management and outcomes in women with thalassaemia major. J Pediatr Endocrinol Metab. 1998;11(3):923–928. [PubMed: 10091166]
  232. Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis. 2006;6(4):226–233. [PubMed: 16554247]
  233. Villeneuve JP, Bilodeau M, Lepage R, Cote J, Lefebvre M. Variability in hepatic iron concentration measurement from needle- biopsy specimens. Journal of Hepatology. 1996;25:172–177. [PubMed: 8878778]
  234. Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol. 2003;123:730–737. [PubMed: 14616979]
  235. Wainscoat JS, Thein SL, Weatherall DJ. Thalassaemia intermedia. Blood Rev. 1987;1:273–279. [PubMed: 3332112]
  236. Walker JM. The heart in thalassaemia. Eur Heart J. 2002 January;23(2):102–105. [PubMed: 11785990]
  237. Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, Evans P, Vichinsky E, Harmatz P. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol. 2006;135:254–263. [PMC free article: PMC2185791] [PubMed: 17010049]
  238. Wang SC, Lin KH, Chern JP, Lu MY, Jou ST, Lin DT, et al. Severe bacterial infection in transfusion-dependent patients with thalassaemia major. Clin Infect Dis. 2003;37(7):984–988. [PubMed: 13130412]
  239. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 2002;100:1566–1569. [PubMed: 12176871]
  240. Weatherall DJ. Thalassaemia intermedia: cellular and molecular aspects. J Hematol. 2001;86 Suppl 1:186–188.
  241. Westwood MA, Anderson LJ, Maceira AM, et al. Normalized left ventricular volumes and function in thalassaemia major patients with normal myocardial iron. J Magn Reson Imaging. 2007 June;25(6):1147–1151. [PubMed: 17520718]
  242. WHO/March of Dimes. 2006 (Report of a joint meeting 5–15 May).
  243. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med. 1985;312:1600–1603. [PubMed: 4000198]
  244. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106:1460–1465. [PMC free article: PMC1895207] [PubMed: 15860670]
  245. Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. Binding of serum ferritin to concanavalin A: patients with homozygous beta thalassaemia and transfusional iron overload. Br J Haematol. 1980;46:409–416. [PubMed: 7448126]
  246. Yarali N, Fisgin T, Duru F, Kara A, Ecin N, Fitoz S, Erden I. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion. J Pediatr Hematol Oncol. 2006;28:11–16. [PubMed: 16394886]
  247. Zurlo MG, De SP, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989 July 1;2(8653):27–30. [PubMed: 2567801]
  248. Zeng YT, Huang SZ, Ren ZR, Lu ZH, Zeng FY, Schechter AN, Rodgers GP. Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis. Br J Haematol. 1995;90(3):557–563. [PubMed: 7646994]

    249. WEBSITES

    1. National Evidence-Based Clinical Guidelines Fertility: assessment and treatment for people with fertility problems_. Feb, 2004. http://www​.rcog.org.uk. [PubMed: 21089236]
    2. RCOG Clinical Green Top Guidelines. Management of HIV in Pregnancy (39) - April 2004. http://www​.rcog.org.uk.
© 2008 Thalassaemia International Federation.

All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from TIF.

Bookshelf ID: NBK173982
Contents

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...